TGFB1 and chronic kidney disease: Approved anti-fibrotic therapies for CKD currently include drugs that modulate the renin-angiotensin-aldosterone system (RAAS), such as ACE inhibitors, ARBs, and statins which likely modulate TGF-β expression [159].